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Abstract
Model-based quantification of drug effect is an efficient tool during pre-clinical and clinical
phases of drug trials. Mathematical modelling can lead to improved understanding of the
underlying biological mechanisms, help in finding short-comings of experimental design
and suggest improvements, or be an effective tool in simulation-based analyses. This thesis
addresses the modelling of time-varying biomarkers both with and without drug-treatment.
Pharmacokinetic/pharmacodynamic models were used to describe observed drug concentra-
tions and biomarkers. These are modelled in the framework of compartmental modelling
described by ordinary differential equations.
This thesis contains two papers in manuscript-form. In the first paper, a meta-analysis was
performed of an existing model and previously published data for the stress-hormone cortisol
and the drug dexamethasone. Cortisol exhibits a circadian rhythm, resembling oscillations,
and is therefore a time-varying target for treatment. The aim was to utilize the model for
prediction of the outcome of a medical test used in veterinary treatments on horses. In
addition to model parameters, inter-individual variability was modelled and estimated in a
Bayesian framework. This allowed simulation of test outcomes for the whole population,
which in turn were used to evaluate available test protocols and suggest improvements.
In the second paper, an improvedmodel was constructed for the cytokine TNFα after challenge
with LPS in addition to intervention treatment. TNFα is not measurable in healthy subjects but
release into blood plasma can be provoked by challenge with LPS. The result is a short-lived
turnover of TNFα. A test compound targeting intervention of TNFα release was included in
the study. Comprehensive experimental data from two studies was available and allowed
to model features of TNFα release, that were not addressed in previously published models.
The final model was then used to analyse the current experimental design and correlations
between LPS challenge and test compound effectiveness. The paper provides suggestions for
future experimental designs.
Keywords: pharmacokinetic/pharmacodynamic modelling, turnover model, TNFα, cortisol,
hierarchical modelling
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1 | Introduction
1.1 Background
Mathematical modelling has become a standard tool in drug development, being routinely
used during pre-clinical and clinical phases of drug discovery and development. In addition,
the created models often accompany requests of approval to government agencies like the
European Medicines Agency or the U.S. Food and Drug Administration. A model typically
encompasses not just the drug itself but also one or multiple targeted biological markers, used
to quantify drug effect. Some examples of these so-called biomarkers are protein-, cytokine-,
or hormone concentration in blood plasma, activity of gene expression or blood pressure.
While mathematical modelling has long been recognized to be of value in drug development,
many challenges still arise due to limited availability of data and limited knowledge or high
complexity of the underlying biology. In the current scientific landscape, especially in the
field of machine learning, ever more complicated black-boxmodels exist, which are capable of
describing data in surprising detail. However, simpler models describing the key mechanisms
are often preferred, favouring interpretability over accuracy.
Two different biological systems were addressed in this work. In Paper 1, the hormone cortisol
that shows a circadian rhythm, i.e. an oscillating pattern with a 24 h period, and its response
to the drug dexamethasone, aimed at reducing cortisol concentration, was explored. The
oscillating pattern as well as sensitivity to stress and pulsatile production make cortisol a
complex biological system. In Paper 2, the cytokine tumor necrosis factor alpha (TNFα), a
small protein important in cell-to-cell signalling in case of inflammation, was investigated.
The complexity of TNFα arises in that it is not measurable in blood plasma in the healthy body.
An external challenge, leading to TNFα release is therefore necessary to be able to observe
TNFα time courses and its response to test compounds, aimed at reducing TNFα release during
challenge. A common and important property of both of these biological systems is that the
biomarker under study is time-varying, both with and without treatment.
Observed data can be used to calibrate a model and therefore parameter estimation stands in
close relation to modelling. The data in this work came from pre-clinical studies collected
on groups of test subjects, exposed to one or multiple dosing regimen. Since test subjects are
typically selected to be similar, they can be considered to be from a common population. A
hierarchical parameter framework was used in both papers, which adds an additional layer
of parameters to describe the common population in relation to individual subjects. This
allows to explicitly quantify variability between subjects, which is of importance when using
the model for prediction purposes (Paper 1). Additionally, if the number of parameters is
large compared to the amount of data available per individual, the parameter hierarchy is
beneficial in regularising the parameter estimation process (Paper 1 and 2).
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1.2 Problem formulation
A thematic question throughout both papers was how mathematical modelling can help to
understand complex biological systems that are time-varying both with andwithout treatment.
Therefore, the goal of the modelling phase was to focus on key features of the respective
time-varying biomarker dynamics. Apart from this, a primary goal in Paper 1 was to use
model prediction to answer questions concerning the design of a medical test protocol used
during veterinary treatment of horses. In Paper 2, the main goal was the construction of an
improved model to describe experimental data and to quantify response to a test compound.
Secondary goals in both papers were to answer questions about drug-effect on the biomarker
as well as to give suggestions for improvements of experimental design in future studies.
1.3 Contributions
The main contributions of Paper 1 are (1) the derivation of an explicit solution to the model
equations in a special case, resulting in initial values and diagnostic plots; (2) successful ap-
plication of a Bayesian parameter estimation workflow to implement the model in a Bayesian
hierarchical framework, with the goal to capture uncertainty stemming from varying data
quality, manifesting itself in parameter uncertainty; (3) illustration of a workflow to analyse
the weaknesses (e.g. false positive rate and sensitivity to the oscillating baseline) of a medical
test protocol through model predictions as well as suggestions for its improvement.
The main contributions of Paper 2 are (1) development of a new model for TNFα after an
external challenge including test compound intervention based on biological and engineering
principles; (2) determination of key parameters from a drug development perspective and
characterisation of test compound effect; (3) discovery of short-comings in experimental
design throughmodel predictions and suggestions for improvement, e.g. pointing out sparsely
sampled periods or the benefits of crossover designs.
1.4 Thesis structure
The rest of this introductory part of the thesis (Chapters 1–3) introduces relevant topics
concerning modelling and parameter estimation, which are necessary to fully appreciate the
content of the two appended papers. This is followed by short summaries of each paper and a
short outlook illustrating ideas for future research.
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2 | Modelling
2.1 Pharmacokinetic/pharmacodynamic modelling
Data was modelled in the framework of pharmacokinetic/pharmacodynamic (PK/PD) mod-
elling [1, 2]. PK/PD models are typically formulated as a set of time-dependent ordinary
differential equations (ODEs) [3] and anchored in ideas from compartmental modelling [4]
and chemical reaction equations [5]. Typically, PK/PDmodels are split into two parts. The PK
model describes how drug concentration changes over time, therefore describing the effect of
the body’s physiology on the drug. The PD model on the other hand describes the dynamics
of one or multiple biomarkers and how their response to drug treatment. These models are
constructed to describe observed time-courses and to determine key quantities relating to the
drug or drug response. An example of a quantity inherent to the drug is the clearance, the rate
at which one unit of volume of drug is eliminated per unit of time. Potency, the concentration
at which the drug achieves 50% of its effect, is an example of an important quantity when
quantifying drug response. In both papers, the focus was on the PD model. The role of the
PK model was to resemble the data empirically and drive the biological response through its
effect on the PD model.
2.2 Compartmental modelling
Compartments can be thought of as containers/buckets containing either an amount or a
concentration of a substance. A compartment is said to be well-mixed in the sense that
incoming or outgoing substance does not lead to a heterogeneous distribution of substance in
the compartment. Instead, contained substance instantaneously uniformly distributes itself
in the compartment. A consequence of this property is that substance in a compartment is
well-described by either its amount or volume and concentration. Compartments are often
given a loose biological interpretation, e.g. a central compartment for concentration of drug
in blood plasma and another compartment for drug in other tissues. This reflects that drug or
any other substance of interest is often not only present in the blood stream, but also in in
other parts of the body.
The models considered in this work were all open systems, in the sense that there was
an inflow, bringing in substance from outside the system, as well as outflow, permanently
eliminating substance. Apart from external inflow and outflow, there are also two types of
flow between compartments. The first is mass transfer of a substance from one compartment
to another during which it may react with another substance. This type of flow respects mass
balance. A typical example is the transport of drug from a gut compartment to a central
compartment, representing concentration in blood plasma (Fig. 2.1). The second type is
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oral dose 𝐴gut 𝐶 ⋅ 𝑉
(1 − 𝐹) ⋅ 𝑘𝑎 ⋅ 𝐴gut
𝐹 ⋅ 𝑘𝑎 ⋅ 𝐴gut 𝐶𝑙 ⋅ 𝐶
Fig. 2.1 A schematic representation of a compartment model describing the fate of a drug
after administration of an oral dose. The drug dose arrives first in the gut compartment, where
the latter contains the amount 𝐴gut of drug. It is then transported with rate of absorption 𝑘𝑎
and bioavailability 𝐹 to a central blood plasma compartment. This compartment is described
by volume 𝑉 and drug concentration 𝐶, resulting in contained drug amount 𝑉 ⋅ 𝐶. Drug
amount is finally eliminated from the body at a rate proportional to drug concentration 𝐶. The
proportionality constant is called the clearance 𝐶𝑙.
control flows, leading to stimulation or inhibition of the production or elimination of one
substance through another. Substance in the controlling compartment is not directly affected
by its effect on the controlled substance.
To demonstrate how a simple compartmental PK model translates to ODEs, consider the
model shown in Fig. 2.1, which is described by the following equations:
d𝐴gut
d𝑡
= −𝑘𝑎 ⋅ 𝐴gut, 𝐴gut(0) = Dose
𝑉 ⋅
d𝐶
d𝑡
= 𝐹 ⋅ 𝑘𝑎 ⋅ 𝐴gut − 𝐶𝑙 ⋅ 𝐶, 𝐶(0) = 0
(2.1)
where 𝐴gut is the amount of drug in the gut compartment, 𝐶 is the concentration of drug in
the blood plasma compartment with volume 𝑉, 𝑘𝑎 the rate of absorption, 𝐹 the bioavailability
of the drug, a number between 0 and 1 determining how much of drug in the gut actually
arrives in the blood stream, and 𝐶𝑙 the clearance of drug from the blood plasma compartment.
A more detailed introduction to compartmental modelling in the context of PK/PD modelling
can be found in [1].
2.3 Turnover models
The turnover model, also called the indirect response model, is a commonly used pharmaco-
dynamic model and is used to model physiological responses whose dynamics is governed by
production as well as elimination processes [1, 6, 7]. The biomarker which is described by the
model, in the following called 𝑅, is typically called the response, even if describing a situation
without drug treatment. The physical dimensions of 𝑅, i.e. whether it is an amount, a concen-
tration or something else, depend on the biomarker under investigation. In its simplest form,
a turnover model can be thought of as a one-compartment model with an inflow described
by a constant rate of production and an outflow proportional to the amount or concentration
contained in the main compartment (Fig. 2.2). The model is described by the ODE
d𝑅
d𝑡
= 𝑘in − 𝑘out ⋅ 𝑅, 𝑅(0) = 𝑅0 (2.2)
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𝑅
𝑘in 𝑘out ⋅ 𝑅
Fig. 2.2 Example of a turnover model with one compartment. The pharmacological response is
represented by its concentration 𝑅. Additionally, 𝑘in is the turnover rate and 𝑘out the fractional
turnover rate.
where 𝑅 is the response, 𝑘in is the turnover rate, describing the rate of production of response,
and 𝑘out is the fractional turnover rate, describing the rate of elimination proportional to 𝑅.
A useful property of this simple model is the existence of a steady state. After an initial
transient phase, the response 𝑅 will converge towards 𝑘in/𝑘out, independently of its initial
state. When modelling drug effect, it is often assumed that the test subject’s response is at
steady state before treatment. This is equivalent to choosing the initial state as
𝑅0 =
𝑘in
𝑘out
. (2.3)
Drug effect on a turnover model is described as stimulation or inhibition of the production or
elimination rate. In both papers presented in this work, the pharmacokinetics of the drug
were assumed to affect the turnover rate. Stimulation and inhibition functions can be linear
or non-linear functions of drug concentration and possibly show saturated behaviour for
increasing drug concentration. Saturation-limited and therefore non-linear interactions have
been used exclusively in this work. These can be modelled by Hill functions which have
their origin in Michaelis-Menten enzyme kinetics and receptor binding [5]. Stimulation 𝑆(𝐶)
and inhibition 𝐼(𝐶) dependent on drug concentration 𝐶 are then described by the following
equations:
𝑆(𝐶) =
𝑆max (
𝐶
𝑆𝐶50
)
𝑛
1 + (
𝐶
𝑆𝐶50
)
𝑛 and 𝐼(𝐶) = 1 −
𝐼max (
𝐶
𝐼𝐶50
)
𝑛
1 + (
𝐶
𝐼𝐶50
)
𝑛 (2.4)
where 0 < 𝑆max is the maximal stimulatory rate, 0 < 𝐼max ≤ 1 is the maximal inhibitory
capacity, 𝑆𝐶50 and 𝐼𝐶50 are respectively the potency of drug for stimulatory and inhibitory
interaction and 𝑛 is a Hill exponent. Note that both 𝑆max and 𝐼max are typically unitless
entities. As an example, in a model with stimulatory drug effect on response production
Eq. 2.2 becomes
d𝑅
d𝑡
= 𝑘in ⋅ 𝑆(𝐶) − 𝑘out ⋅ 𝑅. (2.5)
2.4 Turnover models with a time-varying baseline
It is possible to replace turnover rate and/or fractional turnover rate by time-dependent
functions, as was done in Paper 1. There, the turnover rate was replaced by a cosine function
with a vertical shift and a period of 24 h. This was done to model oscillating production
relative to an average production rate, governed by a circadian rhythm. This was described by
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the function
𝑘in(𝑡) = 𝑘avg ⋅ (1 + 𝛼 ⋅ cos (𝜔(𝑡 − 𝑡0))) , 𝜔 =
2𝜋
24
h−1 (2.6)
where 0 < 𝑘avg is the average turnover rate, 0 < 𝛼 < 1 is the proportional size of the amplitude
of the oscillations in relation to 𝑘avg and 𝑡0 is a phase shift. In this case, the turnovermodel loses
its constant baseline but gains a time-dependent baseline. In this particular case, the baseline
is oscillating, following a scaled version of the turnover rate. One challenge in connection
with time-varying baselines is that drug effect becomes a function of administration time.
This was exemplified in Paper 1 during the analysis of a medical test protocol. Additionally,
determination of ODE initial values accommodating baseline oscillations and quantification
of the time-varying baseline at different levels of drug exposure were addressed in Paper 1.
2.5 Challenge models
Another variant of the turnover model is considered in Paper 2. There, the considered
physiological response did not show a baseline in a healthy subject. Rather, it was necessary
to physically provoke a disease state by means of an external challenge. In terms of a turnover
model this means that there is no endogenous production of the response, i.e. the turnover
rate is zero without administration of the challenge. In the model considered in Paper 2, this
was reflected by formulating the model as
d𝑅
d𝑡
= 𝑆(𝑡) − 𝑘out ⋅ 𝑅, 𝑅(0) = 0 (2.7)
where 𝑆(𝑡) is a time-dependent stimulation term, dependent on the external challenge and
described by a separate part of the model. Response will start at zero, increase due to stimu-
lation at challenge and then tend to zero again as stimulation disappears. This short-lived
transient nature of the response makes these models different from those showing also a
time-varying but cyclic baseline. As before, administration time, now in relation to time
of challenge, is important during compound testing and can have a large influence on the
compounds effectiveness. Another difficulty can be to separate the effect of challenge from
the compound effect, as both are transient effects on the response. Both of these topics have
been addresses in Paper 2.
2.6 Inter-individual variability and hierarchical models
A PK/PD model describes drug concentrations and as well as response in one test subject.
Multiple subjects can be described by the same model, using a different set of parameters for
each subject. In most cases, some or all parameters will show variability between subjects,
so-called inter-individual variability (IIV). Variability is the result of differences between
subjects in drug absorption, distribution and elimination as well as differences in baseline
response and varying response to drug effect. In experimental studies, subjects are chosen
carefully to be as similar as possible. However, differences in weight, metabolism and genetic
variability [8, 9] can lead to noticeable differences in the above-mentioned physiological
functions and therefore to IIV. In addition to this, other factors can have an influence, such as
6
a) b)
Population
parameter model
PK/PD model with
individual parameters
Observations and
residual variance model
Prior knowledge
𝜇 Ω
𝜙𝑖
𝑦𝑖𝑗𝑥𝑖(𝑡) 𝜀𝑖𝑗
Σ
𝑧𝑖
Fig. 2.3 a) Schematic representation of the hierarchy in a population PK/PD model.
b) Graphical representation of all involved variables. This includes prior knowledge informing
population parameters 𝜇 and Ω, and thereby the individual parameters 𝜙𝑖. Model predicted time
courses 𝑥𝑖(𝑡) are related to the individual parameters 𝜙𝑖 and covariates 𝑧𝑖 through the ODE right
hand side 𝑓 (Eq. 2.8). Measurements are related to 𝑥𝑖(𝑡), 𝑧𝑖 and 𝜙𝑖 through model function 𝑔
(Eq. 2.9). Additionally, measurements are related to residual errors with parameters Σ through
model function ℎ (Eq. 2.9). Quantities in greyed out nodes denote observed quantities (𝑧𝑖 and
𝑦𝑖𝑗). All other quantities need to be estimated.
environmental circumstances and subject handling during the experiment. In the present
work IIV as a modelling tool was crucial in both papers. In Paper 1, populations of unobserved
subjects could be simulated by assuming that variability in the observed subjects captured
variability in the general population of subjects. This allowed the prediction of potentially
observable ranges of concentrations and response, which in turn could be used for further
analysis. This would not have been possible otherwise. In Paper 2, modelling with IIV was
used as a tool to reduce model complexity during parameter estimation and for subsequent
analysis of the estimated model. Only some parameters were estimated for all subjects, while
others were assumed to be the same for all subjects. This reduced the amount of parameters
to be estimated and led to improved accuracy.
IIV can be included into a PK/PDmodel by the use of hierarchical modelling [10]. In the field
of drug modelling this is historically called non-linear mixed effects modelling [11]. The idea
is to augment a PK/PD model by an additional layer capturing parameter variability. This is
shown conceptually in Fig. 2.3 a. Experimental observations are described by a PK/PD model
on a per subject basis, each with their own set of individual parameters. A residual variance
model allows for measurement noise and other random influences which are not captured by
the model mechanisms. The statistical distribution of individual parameters is then described
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by an additional population parameter model.
To be able to give an unambiguous description of the parameter model and parameter esti-
mation problem in the following chapter, the description above will now be formalised. For
notational convenience, the time-derivative of a quantity will be indicated by a dot above the
quantity. Assume in the following that there are 𝑁 subjects, indicated by 𝑖 = 1, … ,𝑁. For
subject 𝑖 there are𝑀𝑖 observations, indicated by 𝑗 = 1,… ,𝑀𝑖. These observations are called
𝑦𝑖𝑗 and were collected at time 𝑡𝑖𝑗. A graphical representation of all involved quantities and
their dependencies is shown in Fig. 2.3 b.
Let 𝑥𝑖(𝑡) be a time-dependent vector-valued function describing observed and unobserved
concentration- and response-time courses for subject 𝑖 according to a PK/PD model. In this
work, only PK/PDmodels described by ODEswere considered and it can therefore be assumed
that
̇𝑥𝑖(𝑡) = 𝑓(𝑡, 𝑥𝑖(𝑡); 𝜙𝑖, 𝑧𝑖), 𝑥𝑖(0) = 𝑥0(𝜙𝑖, 𝑧𝑖), (2.8)
where 𝑓(𝑡, 𝑥𝑖(𝑡); 𝜙𝑖, 𝑧𝑖) describes the rate of change for each model component, 𝜙𝑖 is a 𝑑-
dimensional parameter vector, 𝑧𝑖 is a vector of covariates—such as dose, weight, age—and 𝑥0
is the initial state of model components at the starting time of the experiment, which itself
can depend on parameters or covariates.
The goal is to describe vector valued observations 𝑦𝑖𝑗 of drug concentration(s) and/or re-
sponse(s) at time 𝑡𝑖𝑗 for subject 𝑖. Observations 𝑦𝑖𝑗 are described by model predictions and a
residual error. This can be written as
𝑦𝑖𝑗 = 𝑔(𝑡𝑖𝑗, 𝑥𝑖(𝑡𝑖𝑗); 𝜙𝑖, 𝑧𝑖) + ℎ(𝑡𝑖𝑗, 𝑥𝑖(𝑡𝑖𝑗); 𝜙𝑖, 𝑧𝑖, Σ) ⋅ 𝜀𝑖𝑗. (2.9)
Here, 𝑔(𝑡𝑖𝑗, 𝑥𝑖(𝑡𝑖𝑗); 𝜙𝑖, 𝑧𝑖) is a function describing the relation between all model components
and the observed values. This could be as simple as picking one or multiple components
of 𝑥𝑖(𝑡𝑖𝑗) or it could be more involved like a non-linear function of multiple components of
𝑥𝑖(𝑡𝑖𝑗) that cannot be observed separately. The residual error is described by 𝜀𝑖𝑗, a standard
normally distributed vector, i.e. with zero mean and identity covariance matrix, scaled by
ℎ(𝑡𝑖𝑗, 𝑥𝑖(𝑡𝑖𝑗); 𝜙𝑖, 𝑧𝑖, Σ) where Σ is an additional vector of parameters. This makes it possible to
use, e.g. additive errors by setting ℎ ≡ 𝜎 or proportional errors with
ℎ(𝑡𝑖𝑗, 𝑥𝑖(𝑡𝑖𝑗); 𝜙𝑖, 𝑧𝑖, Σ) = 1 + 𝜎 ⋅ 𝑔(𝑡𝑖𝑗, 𝑥𝑖(𝑡𝑖𝑗); 𝜙𝑖, 𝑧𝑖) (2.10)
where 𝜎 > 0 is a parameter in Σ. Different error models can be used for the different
components of the vector 𝑦𝑖𝑗.
Individual parameter vectors 𝜙𝑖 are described by an additional layer in the model hierarchy,
the population parameter model. While restrictive, the following parameter model based
on a normal distribution is in widespread use and sufficient for most use cases. Individual
parameters can be bounded from one or both sides, e.g. most rate parameters are positive.
Assume therefore that 𝜃𝑖 = 𝐹(𝜙𝑖) transforms all individual parameters to the unbounded real
axis. It is then assumed that
𝜃𝑖 ∼ 𝑁(𝜇,Ω) for all 𝑖, (2.11)
where 𝜇 is the mean vector and Ω a covariance matrix, both of which are common to all
subjects. Often, Ω is assumed to be diagonal, but correlations between individual parameters
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can be included. Note that some components of the individual parameter vector 𝜙𝑖 might
not be modelled to include IIV and are then excluded from the distributional assumption in
Eq. 2.11. This leads to these particular components being common to all subjects.
As an example, a parameter 𝜙 bounded between 0 and 1 can be transformed to an unbounded
variable via a logit transform
𝜃 = log (
𝜙
1 − 𝜙
) . (2.12)
Conversely, 𝜃 can be transformed back to a bounded variable with the logistic transform
𝜙 =
1
1 + exp (−𝜃)
. (2.13)
Assuming a normal distribution on 𝜃 is the same as assuming a logit-normal distribution
on 𝜙.
Parameters in hierarchical PK/PD models are typically unknown and need to be estimated.
Methods for parameter estimation will be addressed in the next chapter.
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3 | Parameter estimation
This chapter starts with a short recapitulation of the main ideas behind maximum likelihood
estimation with missing data and sampling of the Bayesian posterior distribution. Thereafter,
the general parameter estimation problem and reviews of the estimation approaches used in
the papers are presented. In Paper 1, a Bayesian posterior distribution of the parameters was
estimated, whereas in Paper 2, maximum likelihood estimates were estimated. In the follow-
ing, the probability density of a variable 𝑥 will be denoted by 𝑝(𝑥). The conditional density
of one variable 𝑥 dependent on another 𝑦 is denoted by 𝑝(𝑥 | 𝑦). The terms distribution and
density will be used inter-changeably, since there is no confusion in this context. Additionally,
a Bayesian mindset [10] is adopted and all parameters as well as data are initially assumed to
be random. When quantities like the vector of individual parameters 𝜙𝑖 appear without an
index, then 𝜙 is the collection of all vectors 𝜙𝑖.
3.1 Preliminaries
In the following, assume that 𝑦 is some observed quantity and 𝜃 a parameter used in a model
describing 𝑦. Using Bayes rule [10], the joint distribution of 𝑦 and 𝜃 can then be written as
𝑝(𝑦, 𝜃) = 𝑝(𝑦 | 𝜃)𝑝(𝜃). (3.1)
Here, 𝑝(𝑦 | 𝜃) is the likelihood and captures the modelled dependency between 𝜃 and 𝑦.
The distribution 𝑝(𝜃) is called the prior distribution of 𝜃, capturing prior beliefs about the
parameter.
3.1.1 Maximum likelihood estimation
In the context of maximum likelihood estimation, the prior distribution is disregarded or,
equivalently, all possible values of 𝜃 are considered to be a priori equally likely. After obser-
vation of the data 𝑦, the likelihood is considered as a function of 𝜃, i.e. 𝐿(𝜃) = 𝑝(𝑦 | 𝜃). The
maximum likelihood estimate (MLE) is the parameter value that maximizes the likelihood
[12].
3.1.2 Expectation-Maximization
Assume now that there is a second parameter 𝜙, which is not directly of interest. As an
example, in case of a hierarchical model, 𝜃 could be a population parameter and 𝜙 a vector of
individual parameters. The individual parameters are necessary to describe the model, but
their estimates might not be of interest. One possible algorithm to calculate the MLE of 𝜃 in
presence of suchmissing data or such nuisance parameters is Expectation-Maximization (EM)
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[12]. The idea behind the algorithm is to alternate between two different types of likelihoods.
𝑝(𝑦, 𝜙 | 𝜃) is called the complete data likelihood and
𝑝(𝑦 | 𝜃) = ∫𝑝(𝑦, 𝜙 | 𝜃) d𝜙 (3.2)
the marginal likelihood. EM alternates between the following steps:
1. Expectation step: Calculation of
𝑄𝑛(𝜃) = 𝔼𝜙 [log𝑝(𝑦, 𝜙 | 𝜃) | 𝑦, 𝜃𝑘−1] (3.3)
2. Maximization step: Calculation of
𝜃𝑛 = argmax
𝜃
𝑄𝑛(𝜃) (3.4)
The feasibility of the algorithm is based on whether or not the expectation in Step 1 can
be calculated. Step 2 is typically solved by a numerical optimization routine and therefore
usually straight-forward. Convergence of this algorithm to a local maximum of the likelihood
has been proved [13].
3.1.3 Sampling from the Bayesian posterior distribution
In a Bayesian context, the goal is the estimation of the posterior distribution of 𝜃 after the
data 𝑦 has been observed. Using Bayes rule, the posterior distribution is proportional to
𝑝(𝜃 | 𝑦) ∝ 𝑝(𝑦 | 𝜃)𝑝(𝜃). (3.5)
In many cases, it is not possible to calculate the posterior distribution in closed form. It is
therefore necessary to find a numerical approximation, for which knowledge of the propor-
tional terms, as in Eq. 3.5, is sufficient. Popular estimation algorithms (Metropolis-Hastings
[14], Metropolis-adjusted Langevin algorithm [15] or Hamiltonian Monte Carlo [16]) all
follow the same general scheme [17].
A parameter 𝜃0 is given as a starting value.
1. A new parameter value 𝜃′ is proposed based on the previous parameter 𝜃𝑛−1, following
a proposal distribution 𝑞(𝜃′ | 𝜃𝑛−1).
2. The acceptance probability is calculated as
𝛼 = min (1,
𝑝(𝜃′ | 𝑦)
𝑝(𝜃𝑛−1 | 𝑦)
⋅
𝑞(𝜃𝑛−1 | 𝜃
′)
𝑞(𝜃′ | 𝜃𝑛−1)
) (3.6)
3. Based on a random sample 𝑢 from a uniform distribution on [0, 1], the new value 𝜃′ is
• rejected if 𝑢 > 𝛼, i.e. 𝜃𝑛 = 𝜃𝑛−1, or
• accepted if 𝑢 ≤ 𝛼, i.e. 𝜃𝑛 = 𝜃
′.
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The algorithms mentioned above differ in how they choose new proposals. Running this
procedure for many iterations returns a set of parameters that can be used to approximate the
posterior distribution of 𝜃. As an example, the expected value of 𝜃 can be approximated with
𝑁 samples by
𝔼[𝜃] =
1
𝑁
𝑁
∑
𝑛=1
𝜃𝑛. (3.7)
3.2 Estimation in hierarchical models
As a short re-capitulation, summarising Eqns. 2.8, 2.9, 2.11, shortening notation and omitting
covariates, the full model for hierarchical PK/PD models is formulated as
̇𝑥𝑖 = 𝑓(𝑡, 𝑥𝑖; 𝜙𝑖), 𝑥𝑖(0) = 𝑥0(𝜙𝑖),
𝑦𝑖𝑗 = 𝑔(𝑡𝑖𝑗, 𝑥𝑖(𝑡𝑖𝑗)) + ℎ(𝑥𝑖(𝑡𝑖𝑗), Σ) ⋅ 𝜀𝑖𝑗,
𝜃𝑖 = 𝐹(𝜙𝑖) ∼ 𝑁(𝜇,Ω).
(3.8)
The goal of the parameter estimation is to get estimates of all unobserved quantities 𝜇, Ω, 𝜙
and Σ after the data and covariates have been observed.
Using Bayes rule, the joint distribution for all involved quantities is
𝑝(𝑦, 𝜇,Ω, Σ, 𝜙) =∏
𝑖
[∏
𝑗
(𝑝(𝑦𝑖𝑗 | 𝜙𝑖, Σ)) 𝑝(𝜙𝑖 | 𝜇,Ω)] 𝑝(𝜇,Ω, Σ). (3.9)
Here, 𝑝(𝑦𝑖𝑗 | 𝜙𝑖, Σ) is called the likelihood of 𝑦𝑖𝑗, 𝑝(𝜙𝑖 | 𝜇,Ω) is the distribution of the indi-
vidual parameters, dependent on population parameters 𝜇 and Ω and 𝑝(𝜇,Ω, Σ) is the prior
distribution for 𝜇, Ω and Σ, holding prior beliefs about these parameters. The data 𝑦 will be
observed during experimentation and by using Eq. 3.9, it is possible to gain information about
unobserved parameters. However, not all unobserved parameters are of equal importance.
Often, population parameters in 𝜇 and Ω are of more interest than individual parameters 𝜙.
Individual parameters can be marginalised out to focus on data and population parameters
𝑝(𝑦, 𝜇,Ω, Σ) =∏
𝑖
[∫(∏
𝑗
𝑝(𝑦𝑖𝑗 | 𝜙𝑖, Σ)) 𝑝(𝜙𝑖 | 𝜇,Ω) d𝜙𝑖] 𝑝(𝜇,Ω, Σ). (3.10)
A number of well-known parameter estimation algorithms for hierarchical PK/PD models
([18, 19, 20]) take advantage of this marginalisation, estimating individual parameters in
hindsight or through computational tricks. One major reason for using Eq. 3.10 instead of
Eq. 3.9 directly, is that the number of parameters can be reduced tremendously, if there is a
large number of subjects involved. In this work, only few subjects per study were available,
and parameter reduction was of lesser importance.
3.3 Note on ODEmodels
Most PK/PDmodels that are formulated as a systemof ODEs cannot be solved analytically. It is
therefore necessary to discretise the time variable 𝑡𝑘, and use numerical solvers to approximate
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model predicted concentrations 𝑥(𝑡𝑘) by ̂𝑥𝑘. The PK/PD models analysed in this work do not
exhibit any chaotic behaviour and fulfil the assumptions of most ODE solvers for reasonable
choices of the parameter vector 𝜙, guaranteeing high accuracy of the approximate solution. It
is therefore assumed that numerical approximation error, stemming from the ODE solver, is
negligible for the purposes of parameter estimation. Note that this is not always the case for
ODE models [21].
3.4 Bayesian posterior distribution
In Paper 1, a Bayesian posterior distribution was estimated for the unknown parameters.
A major goal in that study was to use model predictions to gain an understanding of the
variability of possible response-time courses. After initial model testing and based on results
from a previous study, it was clear that the data showed fluctuations that were not captured by
the model. Considerable uncertainty in parameter estimates was therefore to be expected. A
Bayesian approach was chosen to incorporate parameter uncertainty into model predictions
and to avoid bias or overconfidence in predictions. Additional advantages of Bayesianmethods
are regularisation and incorporation of prior knowledge through the prior distribution. In
this study this was used to set soft boundaries on parameter estimates and use knowledge
from a prior study. A disadvantage of Bayesian posterior sampling, compared to available
maximum likelihood methods, was the runtime of sampling algorithms.
The posterior distribution for hierarchical PK/PD models can be determined from the joint
parameter distribution in Eq. 3.9. Using Bayes rule, the posterior distribution is proportional
to
𝑝(𝜇,Ω, 𝜙, Σ|𝑦) ∝∏
𝑖
[∏
𝑗
(𝑝(𝑦𝑖𝑗 | 𝜙𝑖, Σ)) 𝑝(𝜙𝑖 | 𝜇,Ω)] 𝑝(𝜇,Ω, Σ) (3.11)
Here, 𝑝(𝑦𝑖𝑗 | 𝜙𝑖, Σ) is the likelihood of the individual observations given individual parameters
and residual error variance parameters. The likelihood is a function of 𝜙𝑖 and Σ and no longer
a distribution, since 𝑦𝑖𝑗 is an observed value.
A numerical approximation of the posterior distribution was calculated using the No-U-Turn
sampler (NUTS) [22], an extension to the Hamiltonian Monte Carlo (HMC) algorithm [16],
implemented in the software Stan [23]. HMC uses gradient information of the likelihood
with respect to the unobserved parameters as well as ideas from Hamiltonian mechanics to
choose improved proposals during sampling. The NUTS extension automates adaptation of
HMC’s tuning parameters and potentially improves choice of proposals even further. HMC as
implemented by Stan has been shown to be efficient for parameter estimation in hierarchical
models [24].
3.5 Maximum likelihood estimates
For Paper 2, maximum likelihood estimates of the involved parameters were obtained. Here,
the focus was onmodel building and quick iterations, for whichmaximum likelihoodmethods
are well suited. Compared to the dataset in Paper 1, the available dataset was much cleaner
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and substantially less parameter uncertainty was expected. When the MLEs are used for
simulation from the model, then parameter uncertainty is dropped. Therefore, parameter
uncertainty was considered more important than in the Bayesian case and efforts were made
to keep it low. As a consequence, the number of variables was intentionally kept as small as
possible and not all model parameters were considered to vary between individuals.
Parameters were estimated using the Stochastic Approximation Expectation-Maximization
(SAEM) [20] algorithm, implemented in Monolix [25]. This algorithm uses the marginalised
form of the estimation problem (Eq. 3.10), to obtain a likelihood
𝐿(𝜇,Ω, Σ | 𝑦) =∏
𝑖
[∫(∏
𝑗
𝑝(𝑦𝑖𝑗 | 𝜙𝑖, Σ)) 𝑝(𝜙𝑖 | 𝜇,Ω) d𝜙𝑖]
for the population parameters. The expectation step cannot be solved analytically in this
case, since 𝑝(𝑦𝑖𝑗 | 𝜙𝑖, Σ) depends on the solution of an ODE that depends non-linearly on its
parameters. To find the MLEs for the population parameters the expectation step of the EM
algorithm is replaced by the following two steps:
1. Simulation: Draw a small number of samples 𝜙(𝑘)𝑛 , 𝑘 = 1,… , 𝐾 from
𝑝(𝜙 | 𝑦, 𝜇𝑛−1, Ω𝑛−1, Σ𝑛−1), using for example the Metropolis-Hastings algorithm
2. Stochastic approximation: Set
𝑄𝑛(𝜇,Ω, Σ) = 𝑄𝑛−1(𝜇,Ω, Σ) + 𝛾𝑛 (
1
𝐾
∑
𝑘
log𝑝(𝑦, 𝜙(𝑘)𝑛 | 𝜇,Ω, Σ) − 𝑄𝑛−1(𝜇,Ω, Σ))
This concludes the presentation of background material introduced in Chapters 1–3. The
papers, which are summarised in the following chapter, build on the presented modelling
and parameter estimation techniques, but go further by demonstrating the construction of a
new model and by using a finished model for model predictions.
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4 | Summary of papers
Paper 1: Modelling of oscillatory cortisol response using
a Bayesian population approach for evaluation of dexam-
ethasone suppression test protocols
In this paper, we present a meta-study of a previously published model and dataset [26]. The
model describes time courses of the hormone cortisol as well as the drug dexamethasone
and its effect on cortisol. The previous model was simplified as well as modified to ensure
positivity of predicted cortisol concentrations. In addition, inter-individual variability (IIV)
was included in the model. The main goal was to apply the improved model in the analysis of
overnight dexamethasone suppression test (DST) protocols. The overnight DST is a medical
test used as a tool in the diagnose of a degenerative disease in horses, based on a single
measurement of cortisol concentration.
Challenges were posed by cortisol’s oscillating circadian rhythm, a repeating 24 h pattern,
its sensitivity to stress, which is particularly relevant during experimental handling, and
cortisol’s pulsatile production. Earlier investigations of the data made it clear that uncertainty
in estimated model parameters was not insignificant and would potentially bias the resulting
model prediction. To avoid this bias or overconfidence in predictions, it was necessary to
propagate the parameter uncertainty through themodel. To this end the parameter estimation
problemwas formulated in a Bayesian framework. The posterior distribution was numerically
estimated using Hamiltonian Monte Carlo (HMC) in the software Stan and then used during
model prediction.
Using ideas from Fourier analysis [27], an analytical solution to the PD model was obtained.
It was used for the proper initialisation of the parameter estimation problem as well as to
show the influence of variability on the interaction of steady-state dexamethasone exposure
and the cortisol oscillation. Model simulations were used to investigate two DST protocols.
In particular, how their false positive rates are influenced by protocol design in the context of
IIV and cortisol oscillations. Additionally, the distributions of sensitivity and specificity were
estimated for both DST protocols and compared to previously published experimental values.
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Paper 2: Challengemodel of TNFα turnover at varying LPS
and drug provocations
In this paper, we present a new model for tumor necrosis factor alpha (TNFα) concentration
after challenge with lipopolysaccharides (LPS), additionally incorporating intervention of
TNFα release with a test compound. A difficulty in this study was that the test compound
had to be applied to a time-varying disease model, only showing a short-lived effect after LPS
administration. Data from two pre-clinical studies, that we received from Grünenthal GmbH,
was used during the development and testing of the model. The data included LPS challenge
at multiple levels as well as multiple levels of test compound intervention at a fixed challenge.
Most previously published work on TNFα after LPS challenge only considers one fixed dose
of LPS challenge.
The model was constructed using mechanistic ideas about how LPS triggers TNFα release and
known drug mechanisms. Since data was sparse and the biology behind TNFα is complex
and not fully understood, engineering principles were used to fill in the gaps and build
an empirical model based on observations made during an exploratory data analysis. An
additional difficulty was that LPS time courses were not available. It was therefore necessary
to make assumptions about LPS time course behaviour and connect these to observed TNFα
and drug concentration measurements.
IIV was modelled on key parameters. To determine these, a sensitivity analysis was done
to show which parameters had the largest impact on the individual model. Additional
knowledge from test-runs was used in cases where results from sensitivity analysis were
ambiguous. Parameters were then estimated using the Stochastic Approximation Expectation-
Maximization (SAEM) algorithm, implemented in the software Monolix.
The final model was used to scrutinize the current experimental design and to determine
correlations between LPS challenge and the effectiveness of the test compound. Suggestions
for future experimental designs were given. They include (1) increased sampling after LPS
challenge, to improve capturing the peak location of TNFα response; (2) using a crossover
design including TNFα challenge with and without drug intervention on the same subject, to
be able to determine LPS challenge parameters separately from drug intervention parameters;
and (3) sampling of systemic LPS exposure.
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5 | Outlook
In the work presented here, it was shown that mathematical modelling can be fruitful when
analysing already collected experimental data. Models can be built guided by observed features
in the data combined with knowledge of the underlying biological mechanisms, as was done
in Paper 2. However, some knowledge about the biomarker of interest is typically available,
even in pre-clinical studies. This allows for the construction of a first version of a model
before experiments are conducted. Analysing this model can lead to the discovery of e.g. time
period during which large changes in biomarker time-courses are to be expected or which
model parameters the model output is sensitive to. Using model-based experimental design
can avoid some short-comings as discovered in Paper 2, e.g. sampling sparsely around the
expected location of peak concentration, which itself was of interest in the study. This inverted
approach is not new and used routinely in many studies, especially once a test compound
goes forward into more advanced trial stages. However, it seems to be rather seldom used in a
pre-clinical context.
Using Bayesian methods for parameter estimation in hierarchical PK/PD models is not new
(e.g. [28]). However, even though there are clear benefits with using Bayesian methods,
their use is still not widespread. Reasons for this might be that the theory behind Bayesian
estimation is not aswell-knownas formaximum likelihood, but also due to long computational
run-times. Even when available optimization techniques, such as within-chain parallelisation
(the likelihood calculation is parallelised over subjects during the computation of a new
sample from the posterior distribution), proper parameter tuning and the best possible model
parametrisation were used, running times for the model presented in Paper 1 were still
considerably longer than comparable runs during maximum likelihood estimation. The
number of subjects in this study was small and an even greater run-time is to be expected for
studies based on a larger population of test-subjects. This is of lesser impact when parameters
are estimated for the final version of a model is run and reasonable outcomes can be expected.
During model development however, estimation time is a severe limiting factor. Variational
Bayesian (VB) methods [29] could help to improve on this issue. Similarly to the Expectation-
Maximization algorithm, VB aims to approximate intractable integrals, such as those arising
during marginalisation of the individual parameters (Eq. 3.10).
Fluctuations in cortisol baseline are not accounted for in the model in Paper 1. Stochastic
differential equations (SDEs) could be used as a tool to include unmodelled physiological
processes as system noise. This has been shown to regularise the parameter estimation
[30] and might be able to give hints to the modeller, which parts of the model could be
extended. Using SDE models as an extension to hierarchical PK/PD models is still relatively
new in the field, posing challenges due to scarce availability of estimation algorithms and
communication of results to others who are unfamiliar with the concept of SDEs. Some work
in maximum likelihood estimation in this context has been done (e.g. [31]), whereas Bayesian
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posterior distribution estimation has not been addressed so far. From a technical point of
view, probability distributions need to be estimated, which describe the possible range(s) of
SDE state variables. These estimation procedures often rely on Gaussian approximations,
such as in the Extended Kalman filter (as in [31]). While these algorithms are fast, they
might oversimplify the actual distribution and do not allow for multiple modes. To alleviate
these issues it can be beneficial to use particle filters [32] in the context of particle MCMC
methods [33] for state estimation. This has also previously been done in maximum likelihood
estimation [34] but has not been attempted in a Bayesian setting (to our knowledge).
The main reason for the slow sampling in fully Bayesian methods seems to be two-fold. The
complexity of hierarchical PK/PD models requires the usage of a sophisticated algorithm,
such as Hamiltonian Monte Carlo. However, advanced algorithms require more evaluations
of the likelihood, its gradient and potentially even higher derivatives to efficiently explore the
parameter space. The necessity to solve ODEs during each of these steps creates a substantial
computational load at each step. Some ideas have been proposed [35, 36, 37] suggesting to
replace the numerical solution of the ODEs. One suggestion is to model the data with a
Gaussian process [38] and then estimate ODE parameters by comparing the ODE right hand
side with the derivative of the estimated Gaussian process [35]. However, so far no published
method (to our knowledge) has outperformed Bayesian sampling with explicit numerical
integration.
When the biological response is in focus, as was the case in both papers in this thesis, then
PK concentration-time data is typically only modelled empirically by resembling the shape
of the data, without much thought of the underlying physiological mechanisms—as would
be the case in a physiologically based PK (PBPK) model [39]. This step could be replaced
by an empirical, data-driven model based on a Gaussian process model. This would make it
unnecessary to choose between different compartmental models. A choice which is often
based on a purely statistical measure (e.g. Akaike’s information criterion) without relating to
the underlying biology. One unsolved problem would be how inter-individual variability can
be included when PK concentration time-courses are described by a Gaussian process.
In conclusion, this work provides contributions to hierarchical PK/PD modelling and model-
based prediction as well as some smaller contributions regarding implementation of hierar-
chical PK/PD models in a Bayesian framework and mathematical model analysis.
20
References
1. Gabrielsson J, Weiner D (2016) Pharmacokinetic & Pharmacodynamic Data Analysis:
Concepts and Applications, 5th edn. Swedish Pharmaceutical Press, Stockholm
2. Ette EI, Williams PJ (2007) Pharmacometrics: The Science of Quantitative Pharmacology.
Wiley-Interscience, New York
3. Teschl G (2012) Ordinary Differential Equations and Dynamical Systems. American
Mathematical Society
4. Anderson DH (1983) Compartmental Modeling and Tracer Kinetics. Springer-Verlag,
Berlin Heidelberg
5. Atkins P, de Paula J, Keeler J (2017) Atkins’ Physical Chemistry, 11th edn. Oxford Univer-
sity Press
6. Dayneka NL, Garg V, Jusko WJ (1993) Comparison of Four Basic Models of Indirect
Pharmacodynamic Responses. J Pharmacokinet Biopharm 21:457–478
7. Sharma A, Jusko WJ (1998) Characteristics of indirect pharmacodynamic models and
applications to clinical drug responses. Br J Clin Pharmacol 45:229–239
8. Wilkinson GR (2005) Drug Metabolism and Variability among Patients in Drug Response.
N Engl J Med 352(21):2211–2221, DOI 10.1056/NEJMra032424
9. Roden DM, George Jr AL (2002) The genetic basis of variability in drug responses. Nat
Rev Drug Discov 1:37–44, DOI 10.1038/nrd705
10. Gelman A, Carlin JB, Stern HS, Dunson DB, Vehtari A, Rubin DB (2013) Bayesian Data
Analysis, 3rd edn. CRC Press, Boca Raton, Florida
11. Davidian M, Giltinan DM (1995) Nonlinear Models for Repeated Measurement Data.
Chapman & Hall/CRC, Boca Raton, Florida
12. Casella G, Berger RL (2002) Statistical Inference, 2nd edn. Duxbury, Pacific Grove, CA
13. Wu CFJ (1983) On the Convergence Properties of the EM Algorithm. Ann Stat 11:95–103
14. Hastings WK (1970) Monte Carlo Sampling Methods Using Markov Chains and Their
Applications. Biometrika 57:97––109, DOI 10.1093/biomet/57.1.97
15. Roberts GO, Rosenthal JS (1998) Optimal scaling of discrete approximations to langevin
diffusions. J R Stat Soc Series B 60:255–268, DOI 10.1111/1467-9868.00123
16. Neal RM (2011) MCMC Using Hamiltonian Dynamics. In: Brooks S, Gelman A, Jones
GL, Meng XL (eds) Handbook of Markov Chain Monte Carlo, CRC Press, New York
17. Robert CP, Casella G (2004) Monte Carlo Statistical Methods, 2nd edn. Springer Sci-
ence+Business Media, New York
21
18. Wang Y (2007) Derivation of various NONMEM estimation methods. J Pharmacokinet
Pharmacodyn 34:575–593, DOI 10.1007/s10928-007-9060-6
19. Almquist J, Leander J, Jirstrand M (2015) Using sensitivity equations for computing
gradients of the FOCE and FOCEI approximations to the population likelihood. J Phar-
macokinet Pharmacodyn 42:191–209, DOI 10.1007/s10928-015-9409-1
20. Delyon B, Lavielle M, Moulines E (1999) Convergence of a stochastic approximation
version of the EM algorithm. Ann Stat 27:94–128, DOI 10.1214/aos/1018031103
21. Chkrebtii OA, Campbell DA, Calderhead B, Girolami MA (2016) Bayesian Solution
Uncertainty Quantification for Differential Equations. Bayesian Anal 11:1239–1267
22. HoffmanMD, GelmanA (2014) The No-U-Turn Sampler: Adaptively Setting Path Lengths
in Hamiltonian Monte Carlo. J Mach Learn Res 15:1593–1623, URL http://jmlr.org/
papers/v15/hoffman14a.html
23. Carpenter B, Gelman A, Hoffman MD, Lee D, Goodrich B, Betancourt M, Brubaker M,
Guo J, Li P, Riddell A (2017) Stan: A Probabilistic Programming Language. J Stat Softw
76, DOI 10.18637/jss.v076.i01, URL http://www.jstatsoft.org/v76/i01/
24. Betancourt M, Girolami M (2013) Hamiltonian Monte Carlo for Hierarchical Models.
URL http://arxiv.org/abs/1312.0906
25. Lixoft SAS (2018) Monolix version 2018R2. URL http://lixoft.com/products/
monolix/
26. Ekstrand C, Ingvast-Larsson C, Olsen L, Hedeland M, Bondesson U, Gabrielsson J (2016)
A quantitative approach to analysing cortisol response in the horse. J Vet Pharmacol Ther
39:255–263, DOI 10.1111/jvp.12276
27. Folland GB (2009) Fourier Analysis and its Applications. American Mathematical Society,
Belmont, California
28. Lunn DJ, Best N, Thomas A, Wakefield J, Spiegelhalter D (2002) Bayesian analysis of
population PK/PDmodels: general concepts and software. J Pharmacokinet Pharmacodyn
29:271–307
29. Beal MJ (2003) Variational algorithms for approximate Bayesian inference. PhD thesis,
University College London
30. Leander J, Lundh T, Jirstrand M (2014) Stochastic differential equations as a tool to
regularize the parameter estimation problem for continuous time dynamical systems
given discrete timemeasurements.Math Biosci 251:54–62, DOI 10.1016/j.mbs.2014.03.001
31. Olafsdottir HK, Leander J, Almquist J, Jirstrand M (2018) Exact gradients improve pa-
rameter estimation in nonlinear mixed effects models with stochastic dynamics. AAPS J
20, DOI 10.1208/s12248-018-0232-7
32. Del Moral P (2004) Feynman-Kac Formulae: Genealogical and Interacting Particle Sys-
tems with Applications. Probability and its Applications, Springer, New York, NY
33. Schön TB, Svensson A, Murray L, Lindsten F (2018) Probabilistic learning of nonlinear
dynamical systems using sequential monte carlo. Mech Syst Signal Process 104:866–883
22
34. Donnet S, Samson A (2011) EM algorithm coupled with particle filter for maximum
likelihood parameter estimation of stochastic differential mixed-effects models. MAP5
2010-24, URL https://hal.archives-ouvertes.fr/hal-00519576v2
35. Calderhead B, Girolami M, Lawrence ND (2008) Accelerating Bayesian inference over
nonlinear differential equationswithGaussian processes. Advances inNeural Information
Processing Systems 21:217–224
36. Dondelinger F, Filippone M, Rogers S, Husmeier D (2013) ODE parameter inference
using adaptive gradient matching with Gaussian processes. In: Sixteenth International
Conference on Artificial Intelligence and Statistics
37. Wang Y, Barber D (2014) Gaussian Processes for Bayesian Estimation in Ordinary Dif-
ferential Equations. In: Proceedings of the 31st International Conference on Machine
Learning, vol 32
38. Rasmussen CE, Williams CKI (2006) Gaussian Processes for Machine Learning. MIT
Press
39. Rowland M, Peck C, Tucker G (2011) Physiologically-based pharmacokinetics in drug
development and regulatory science. Annu Rev Pharmacol Toxicol
23
24
